sharon sanders
Editor-in-Chief & President
<table style="text-align: left; direction: ltr;" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="nav" align="center"> Industry Committee of the Shura to discuss the future of medicine in Alexandria
The proliferation of fake and smuggled drugs due to poor control
of patents and 40% foreign manufacturing excellence
</td></tr><tr><td class="auther" align="right">
</td></tr><tr><td align="right">
The Commission's Energy and Industry Advisory Council, chaired by Mohamed Farid Khamis, during a meeting with leaders of the pharmaceutical industry and the Chamber of Commerce in Alexandria and in the presence of the governor, Major General Adel Labib, the veil of the challenges to the pharmaceutical industry and its dependence on the importation of some 63% of the raw materials, raising the cost of production as well as to increase the funding burden.
Pointed out that the provisions of control to the Egyptian market, which led to the spread of the phenomenon of fake and smuggled drugs are harmful to the health of citizens.
Referring to the difficulty of medical registration in Western Asia and Eastern Europe and the impediments to the export markets of the Arab and African countries.
Pharmaceutical companies have been of Arab, faces stiff competition from multinational companies in addition to the policies of dumping by the industrialized countries, which leads to the decline of the industry in the long run, and the high prices of pharmaceutical products to add the medicine to the problem of the food problem in the region.
The Committee noted that the patents in the Arab world does not exceed 5% of the total drugs produced and consumed in the form of manufacturing with distinction from the foreign companies 40%, and the adoption of many of the Arab markets on the full import of medicines before the one in the Arab markets are the privilege of manufacturing in Egypt, 40% Syria and Saudi Arabia 50%, and 60%, Morocco 90%, Yemen 29% and 36% of Tunisia, Jordan, 2%.
Indicate that foreign companies that the size of the assets of any of them to more than 130 billion dollars, while the investments of the Arab countries scattered between 4 to $ 5 billion and more than Arab companies that have factories in the capital of 100 companies is weak and mostly confined to its role in the tradition of medicine rather than to provide patents and the Arab countries imported 25% of its direct addition to manufacturing excellence, which is not often beyond the scope of the products of tradition, no need for the local market.
The Commission proposed the formulation of drug policy is transparent and a strategy for improving the situation of medicine and to take defensive action to take advantage of the opportunities provided by the TRIPS agreement and the amendment to the registration system so that drugs do not exceed the registration period of 6 months for each type of medicine with the flags of the applicant's consideration of their registration dates and the development of policy and a new mechanism for the pricing of medicines importer and the factory to achieve a balance between the interests of citizens and the interests of manufacturers and pharmaceutical companies call for the establishment of research centers and the development of pharmaceutical and a supreme council to control the prices of medicine to be made available to citizens at affordable prices and a fund for the support of pharmaceutical services. </td></tr></tbody></table>
http://www.algomhuria.net.eg/algomhuria/today/thirdp/detail02.asp
انتشار الأدوية المهربة والمغشوشة بسبب ضعف الرقابة
The proliferation of fake and smuggled drugs due to poor control
5% براءات اختراع و40% بامتياز تصنيع أجنبي
5% of patents and 40% foreign manufacturing excellence
</td></tr><tr><td class="auther" align="right">
عبد الوهاب عدس
Abdel-Wahab Adass</td></tr><tr><td align="right">
كشفت لجنة الصناعة والطاقة بمجلس الشوري برئاسة محمد فريد خميس خلال اجتماعها مع قيادات صناعة الدواء والغرفة التجارية بالإسكندرية وبحضور المحافظ اللواء عادل لبيب النقاب عن التحديات أمام صناعة الدواء واعتمادها علي استيراد نحو 63% من المواد الخام مما يرفع من تكلفة الانتاج بالاضافة لزيادة الاعباء التمويلية.
The Commission's Energy and Industry Advisory Council, chaired by Mohamed Farid Khamis, during a meeting with leaders of the pharmaceutical industry and the Chamber of Commerce in Alexandria and in the presence of the governor, Major General Adel Labib, the veil of the challenges to the pharmaceutical industry and its dependence on the importation of some 63% of the raw materials, raising the cost of production as well as to increase the funding burden.
اشارت إلي عدم احكام الرقابة علي السوق المصري مما أدي لتفشي ظاهرة الأدوية المهربة والمغشوشة الضارة بصحة المواطنين.
Pointed out that the provisions of control to the Egyptian market, which led to the spread of the phenomenon of fake and smuggled drugs are harmful to the health of citizens.
اشارت إلي صعوبة التسجيل الدوائي في غرب آسيا وشرق أوروبا ومعوقات التصدير للأسواق العربية والافريقية.
Referring to the difficulty of medical registration in Western Asia and Eastern Europe and the impediments to the export markets of the Arab and African countries.
تعرضت شركات الدواء العربية لمنافسة شديدة من الشركات متعددة الجنسية علاوة علي سياسات الاغراق التي تقوم بها الدول الصناعية الأمر الذي يؤدي إلي تراجع هذه الصناعة علي المدي البعيد وارتفاع أسعار المنتجات الدوائية لتضاف مشكلة الدواء إلي مشكلة الغذاء في المنطقة.
Pharmaceutical companies have been of Arab, faces stiff competition from multinational companies in addition to the policies of dumping by the industrialized countries, which leads to the decline of the industry in the long run, and the high prices of pharmaceutical products to add the medicine to the problem of the food problem in the region.
واشارت اللجنة إلي ان براءات الاختراع في العالم العربي لا تتعدي 5% من اجمالي الأدوية المستهلكة والمنتجة في حين تشكل نسبة التصنيع بامتياز من شركات أجنبية 40% وتعتمد الكثير من الأسواق العربية علي الاستيراد بالكامل فنجد الأدوية المطروحة في الأسواق العربية بامتياز تصنيع تمثل في مصر 40% وسوريا 50% والسعودية 60% والمغرب 90% واليمن 29% وتونس 36% والاردن 2%.
The Committee noted that the patents in the Arab world does not exceed 5% of the total drugs produced and consumed in the form of manufacturing with distinction from the foreign companies 40%, and the adoption of many of the Arab markets on the full import of medicines before the one in the Arab markets are the privilege of manufacturing in Egypt, 40% Syria and Saudi Arabia 50%, and 60%, Morocco 90%, Yemen 29% and 36% of Tunisia, Jordan, 2%.
اشارت إلي أن الشركات الأجنبية التي يصل حجم اصول أي منها إلي ما يزيد علي 130 مليار دولار بينما استثمارات الدول العربية متفرقة ما بين 4 5 مليارات دولار ولا تتعدي الشركات العربية التي لديها مصانع في المنطقة 100 شركة برءوس أموال ضعيفة وينحصر دورها في الغالب علي تقليد الدواء وليس تقديم براءات اختراع وتستورد الدول العربية 25% من احتياجاتها بشكل مباشر بالاضافة إلي التصنيع بامتياز والذي غالبا لا يخرج عن نطاق التقليد لمنتجات لا حاجة للسوق المحلي بها .
Indicate that foreign companies that the size of the assets of any of them to more than 130 billion dollars, while the investments of the Arab countries scattered between 4 to $ 5 billion and more than Arab companies that have factories in the capital of 100 companies is weak and mostly confined to its role in the tradition of medicine rather than to provide patents and the Arab countries imported 25% of its direct addition to manufacturing excellence, which is not often beyond the scope of the products of tradition, no need for the local market.
واقترحت اللجنة صياغة سياسة دوائية تتصف بالشفافية واستراتيجية للارتقاء بحالة الدواء واتخاذ إجراءات دفاعية للاستفادة من الفرص التي توفرها اتفاقية تربس وتعديل نظام التسجيل للأدوية بحيث لا تتعدي فترة التسجيل عن 6 شهور لكل صنف دواء مع اعلام مقدم طلب التسجيل بمواعيد نظر طلباتهم ووضع سياسة وآلية جديدة لتسعير الدواء المستورد والمصنع بما يحقق التوازن بين مصلحة المواطنين ومصلحة الشركات المنتجة ودعوة شركات الدواء لانشاء مراكز بحوث وتطوير دوائية ومجلس أعلي لمراقبة أسعار الدواء لتوفيره للمواطنين بأسعار مناسبة وصندوق لدعم الخدمات الدوائية.
The Commission proposed the formulation of drug policy is transparent and a strategy for improving the situation of medicine and to take defensive action to take advantage of the opportunities provided by the TRIPS agreement and the amendment to the registration system so that drugs do not exceed the registration period of 6 months for each type of medicine with the flags of the applicant's consideration of their registration dates and the development of policy and a new mechanism for the pricing of medicines importer and the factory to achieve a balance between the interests of citizens and the interests of manufacturers and pharmaceutical companies call for the establishment of research centers and the development of pharmaceutical and a supreme council to control the prices of medicine to be made available to citizens at affordable prices and a fund for the support of pharmaceutical services. </td></tr></tbody></table>
http://www.algomhuria.net.eg/algomhuria/today/thirdp/detail02.asp